ArticleFrontiers in oncology2026
Predicting preoperative axillary lymph node metastasis to guide surgical decisions in invasive breast cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRI-Based Intratumoral and Multi-Range Peritumoral Radiomics for Predicting Axillary Lymph Node Metastasis in Breast Cancer.International journal of general medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the clinical management of patients with invasive breast cancer (IBC), the precise identification of axillary lymph node metastasis (ALNM) is of paramount importance for guiding axillary surgery and formulating corresponding treatment strategies. Currently, the clinical need to accurately predict the risk of ALNM in patients with IBC, so as to determine whether axillary surgery (including sentinel lymph node biopsy) can be safely omitted, has not been fully met. Methods: The clinical data of 454 patients with IBC were retrospectively analyzed, and the patients were randomly divided into a training group and a validation group at a ratio of 3:1. Independent predictors related to ALNM were identified through univariate and multivariate Logistic regression analysis. Accordingly, a nomogram model integrating clinicopathological, ultrasound and serological indicators along with additional clinical parameters was constructed and validated by receiver operating characteristic (ROC) curve analysis, calibration plots, and decision curve analysis (DCA). The primary outcome measure was the incidence of ALNM. Results: The ALNM rates were 31.4% and 27.4% in the training and verification groups, respectively. Multivariate regression analysis indicated that tumor size, circumscribe margin, ultrasonic lymph node status, WBC, ER, and BI-RADS were independent risk factors for ALNM in patients with IBC. In both the training group and the validation group, the nomogram exhibited modest predictive performance (training group AUC = 0.741; validation group AUC = 0.705). The Ultrasonic lymph node status (normal vs. abnormal) alone yielded an AUC of 0.620 in the training cohort and 0.627 in the validation cohort for predicting ALNM. In comparison, our nomogram achieved significantly higher AUCs (training: 0.741, P = 0.0017; validation: 0.705, P = 0.1772; DeLong test). Additionally, the nomogram demonstrated satisfactory calibration and clinical utility as evidenced by the calibration curve and DCA. Conclusion: By integrating clinicopathological, ultrasonic and serological indicators, this nomogram can enhance the accuracy of predicting ALNM in patients with IBC. However, given its moderate discriminative ability, the model can support preoperative risk stratification but cannot replace standard axillary staging procedures (including sentinel lymph node biopsy). Our findings provide a basis for decision-making regarding individualized axillary lymph node surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.